Annual Report

Overview

The report describes a year of innovation-led transformation, with 2024 revenue of RMB15.619 billion and a respiratory pipeline of more than ten innovative drugs. ESG governance was strengthened through a Board Sustainability Committee and ESG-linked management performance indicators. Environmental initiatives reported carbon-emission reductions of 5,122.64 tons, while rural chronic-disease programs benefited more than 30,000 low-income individuals. The report also notes an AA MSCI ESG rating and inclusion in the S&P Global Sustainability Yearbook.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2024
Period: 1 January 2024 – 31 December 2024
Publication date: 7 April 2025
Language: English
Pages
File size

Reporting standards, commitments and assurance details are available with a free account.

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services